真菌耐药性机制及治疗进展(2)
[8] White TC,Mark KA,Bowden RA.Clinical,cellular,and monlecular factors that coritbute to antifungal drug resistance.Clin Microbiol Rev 1998,11(2)：372-402.
[9] Nolte FS,Parkinson T,Falconer DJ,et al.Isolation and characterization of fluconazole and amphotericin b-resistant candida albicans from blood of tow patients with leukemia.Antimicrob Agents Chemother，1997,44(1)：196-199
[10]Ramananodraibe E,Younsi M,Coulon J,et al. Implication of cell wall constituents in the sesitivety of kluyveromyces lactis stains to amphotericin B.Res Microbiol,1998,149(2)：109-118.
[11]Yamaguchi H.Molecular and biochemical mechanisms of drag restance in fungi.J Nippon Ishinkin Gakkai，1999,40(4)：199-208.
[12]Sanz-Rodriguez C,Lopea_Duarte M,Jurado M,et al.Safety of the concomitant use of caspofungin and cyclosporine A patients with in-vasive fungal infections[J].Bone Marrow Transplant,2004,34(1)：13-20.
[13]Mora-Durte J,Betts,Rostaein C,et al.Comparison of caspofungin and amphotericin B for invasive candidiasis[J].N Engl J Med,2002,347：2020-2029.
[14]Herbracht R,Denning DW,Patterson TF,et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillsis[J].N Engl J Med,2002,347：408-415.
[15]RexJH,Pappas PG,Karchmer AW,et al.Arandomized and blinded multicenter trial of hig-dose flconazole plus placebo versus fluconazole plus amphotericin B as therypy for candidemia and its consequences in nonneutropenic subjects[J].Clin Infect Dis，2003，36：1221-1228.
[16]Aliff TB,Maslak PG,jurcic JG,et al.Refactory aspergillus pneuminia in patients with acute leukemia：successful therapy with combination caspofungin and liposomalamphotercin[J]. Cancer，2003,97：1025-1032., 百拇医药(苏力德 廖 宁)
[9] Nolte FS,Parkinson T,Falconer DJ,et al.Isolation and characterization of fluconazole and amphotericin b-resistant candida albicans from blood of tow patients with leukemia.Antimicrob Agents Chemother，1997,44(1)：196-199
[10]Ramananodraibe E,Younsi M,Coulon J,et al. Implication of cell wall constituents in the sesitivety of kluyveromyces lactis stains to amphotericin B.Res Microbiol,1998,149(2)：109-118.
[11]Yamaguchi H.Molecular and biochemical mechanisms of drag restance in fungi.J Nippon Ishinkin Gakkai，1999,40(4)：199-208.
[12]Sanz-Rodriguez C,Lopea_Duarte M,Jurado M,et al.Safety of the concomitant use of caspofungin and cyclosporine A patients with in-vasive fungal infections[J].Bone Marrow Transplant,2004,34(1)：13-20.
[13]Mora-Durte J,Betts,Rostaein C,et al.Comparison of caspofungin and amphotericin B for invasive candidiasis[J].N Engl J Med,2002,347：2020-2029.
[14]Herbracht R,Denning DW,Patterson TF,et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillsis[J].N Engl J Med,2002,347：408-415.
[15]RexJH,Pappas PG,Karchmer AW,et al.Arandomized and blinded multicenter trial of hig-dose flconazole plus placebo versus fluconazole plus amphotericin B as therypy for candidemia and its consequences in nonneutropenic subjects[J].Clin Infect Dis，2003，36：1221-1228.
[16]Aliff TB,Maslak PG,jurcic JG,et al.Refactory aspergillus pneuminia in patients with acute leukemia：successful therapy with combination caspofungin and liposomalamphotercin[J]. Cancer，2003,97：1025-1032., 百拇医药(苏力德 廖 宁)